, from participants in KEEP, a community-based health-screening program targeting individuals 18 years and older with diabetes, hypertension, or family history of kidney disease, diabetes, or hypertension. Anemia was defined as hemoglobin level less than 13.5 g/dL for men and less than 12.0 g/dL for women (Kidney Disease Outcomes Quality Initiative [KDOQI] 2006) or less than 13.0 g/dL for men and less than 12.0 g/dL for women (World Health Organization [WHO]).
C
hronic kidney disease (CKD) is highly prevalent in the US population, with recent estimates indicating that up to 16 .5% of people aged 20 years or older have the disease. 1 African Americans and other racial and ethnic minority groups are at increased risk of CKD. 2, 3 Anemia is a common complication of CKD and is associated with increased risk of cardiovascular disease (CVD), morbidity, and mortality, particularly in high-risk populations. 4, 5 CVD risk in patients with CKD involves traditional and nontraditional risk factors. [4] [5] [6] [7] [8] [9] Traditional risk factors include diabetes, hypertension, obesity, dyslipidemia, smoking, and advanced age. 8 Nontraditional risk factors include hyperhomocysteinemia, hyperparathyroidism, hyperphosphatemia, endothelial dysfunction, diastolic dysfunction, and anemia, which is increasingly recognized in this patient population. 6, 7, 9 Anemia of CKD generally is attributed to absolute or relative erythropoietin deficiency. However, other factors, such as iron deficiency, blood loss, shortened red blood cell life span, and inflammation, may contribute to its development. 10, 11 In the general population, anemia is more prevalent and severe in African Americans than whites.
12, 13 Although racial and ethnic differences in anemia prevalence and severity were noted in patients with CKD, 14 the extent and characteristics of anemia in populations at risk of CKD are less well defined. Early identification of anemia, particularly in high-risk populations, could lead to effective preventive and therapeutic strategies to improve outcomes. Thus, better understanding of the characteristics of this population has potential public health benefits. We examined the prevalence and associations of anemia in participants in the Kidney Early Evaluation Program (KEEP), a large free communitybased CKD screening program, and compared them with the National Health and Nutrition Examination Survey (NHANES) 1999-2004, a representative sample of the US general population. KEEP targets high-risk populations; eligible participants are 18 years or older and have a personal or family history of diabetes or hypertension or a family history of kidney disease. Conversely, NHANES 1999-2004 surveys were targeted toward randomized cohorts that are generalizable to the US population.
The objectives of this study are to: (1) assess the prevalence of anemia in the KEEP and NHANES populations by risk groups, including age, sex, race, diabetes, and CVD, by using National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) and World Health Organization (WHO) anemia definitions; (2) assess the prevalence of CKD stages in anemic patients across the different risk groups in the KEEP and NHANES cohorts; and (3) identify factors associated with significant odds of anemia in the CKD high-risk population of the KEEP program.
METHODS

Definitions
KEEP and the NHANES database are fully described elsewhere in this supplement. 15 Disease definitions are as follows. History of diabetes is defined as self-reported diabetes or retinopathy, and history of hypertension, as selfreported hypertension. Anemia is defined as hemoglobin level less than 13.5 g/dL (Ͻ135 g/L) for men and less than 12.0 g/dL (Ͻ120 g/L) for women (KDOQI 2006) 10 or less than 13.0 g/dL (Ͻ130 g/L) for men and less than 12.0 g/dL (Ͻ120 g/L) for women (WHO). Obesity is defined as body mass index of 30 kg/m 2 or greater. History of CVD in KEEP is defined as self-reported heart attack, heart bypass surgery, heart angioplasty, stroke, heart failure, abnormal heart rhythm, or peripheral arterial disease (survey form in use before May 2005). NHANES defined history of CVD (applicable only to participants Ն20 years) as self-reported history of coronary heart disease, angina/angina pectoris, heart attack, congestive heart failure, or stroke. Estimated glomerular filtration rate (eGFR) was determined by using the isotope-dilution mass spectrometry 4- ).
Statistical Analysis
Prevalence of anemia was analyzed with risk factors by using both the KDOQI and WHO definitions. Multiple logistic regression was used to determine the independent relationships between anemia outcome and associations, including age; sex; race; screening year; education; smoking status; personal history of diabetes, hypertension, or CVD; family history of diabetes or hypertension; obesity; and CKD. P less than 0.05 is considered statistically significant.
RESULTS
The population screened for the KEEP program included 70,069 eligible participants. Anemia data were collected for all participants and data for key variables were collected for 51,727 (73.8% *All analyses related to smoking status or cardiovascular disease are limited to participants 20 years and older. †KDOQI: hemoglobin level less than 13.5 g/dL (Ͻ135 g/L) for men and less than 12 g/dL (Ͻ120 g/L) for women. ‡WHO: hemoglobin level less than 13.0 g/dL (Ͻ130 g/L) for men and less than 12 g/dL (Ͻ120 g/L) for women.
study cohort than KEEP: smoking, 24.9% in NHANES versus 12.1% in KEEP, and low education level, 21.6% versus 15.5%. Using the KDOQI definition, the prevalence of anemia in KEEP participants was 2.2 times greater than in NHANES participants (13.9% versus 6.3%; Table 1 ). Greater anemia prevalence in KEEP was observed consistently across age and racial groups in both sexes and for each risk factor examined, including obesity, hypertension, diabetes, and CVD. Anemia (defined by KDOQI) was lower in current smokers compared with nonsmokers (KEEP, 9.8% versus 14.3%; NHANES, 3.6% versus 7.2%). Applying the WHO definition, results were similar, with anemia prevalence 2.2 times greater in the KEEP population than in the NHANES population (11.8% versus 5.3%). Results also were similar for smokers using the WHO anemia definition.
Mean hemoglobin level was lower in KEEP Table 2 ). KEEP mean hemoglobin values for patients with CKD by stage are significantly different (P Ͻ 0.001), as follows: non-CKD, 13. 
Smoking, Anemia, and CKD
Using the KDOQI definition, anemia was less prevalent in current smokers in both the KEEP (8.6% for smokers, 12.6% for nonsmokers) and NHANES (14.0%, 25.3%) populations (Table 3) . Results were similar using WHO anemia guidelines. The prevalence of anemia by smoking status for KEEP and NHANES is shown in Fig 1, and prevalence of anemia by CKD stages is shown in Fig 2. 
Sex Differences
Using the KDOQI definition, anemia was more prevalent in KEEP men than women (15.5% versus 13.2%; Table 2 ). In participants with anemia, using the KDOQI definition, greater proportions of men than women had advanced CKD (KEEP, 35.1% versus 27.6%; NHANES, 28.2% versus 15.7%; Table 4 ). Results were similar using the WHO anemia guidelines.
We used a multivariate logistic regression model that considered the odds of anemia in KEEP participants, a high-CKD-risk population. Using KDOQI guidelines, men had greater odds of anemia than women (odds ratio [OR], 1.30; 95% confidence interval [CI], 1.23 to 1.37; P Ͻ 0.001; Table 5 ). Conversely, using the WHO anemia definition, odds were lower for men than women (OR, 0.68; 95% CI, 0.64 to 0.72; P Ͻ 0.001), reflecting the greater threshold of anemia detection in men, whereas the threshold for women was the same in the KDOQI and WHO definitions.
Racial/Ethnic Differences
Prevalences of anemia were greatest for African Americans in both the KEEP and NHANES cohorts (Table 1) . In KEEP participants, using the KDOQI definition, prevalences of anemia were 21.7% for African Americans, 9.9% for whites, and 9.1% for Hispanics. NHANES data also showed a greater prevalence of anemia in African Americans. A similar pattern of racial 
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distribution was observed using WHO anemia criteria.
Mean hemoglobin values were lowest in African Americans compared with other racial and ethnic groups in both KEEP and NHANES databases (Table 2) , whereas values for Hispanics and whites were similar. In the KEEP cohort, average hemoglobin levels were 13.2 g/dL (132 g/L) for African Americans, 14.0 g/dL (140 g/L) for Hispanics, and 14.0 g/dL (140 g/L) for whites. *All analyses related to smoking status or cardiovascular disease limited to participants aged 20 years or older. †KDOQI: hemoglobin level less than 13.5 g/dL (Ͻ135 g/L) for men and less than 12 g/dL (Ͻ120 g/L) for women. ‡WHO: hemoglobin level less than 13.0 g/dL (Ͻ130 g/L) for men and less than 12 g/dL (Ͻ120 g/L) for women.
Similarly, in the NHANES cohort, hemoglobin levels were 13.6 g/dL (136 g/L) for African Americans, 14.6 g/dL (146 g/L) for Hispanics, and 14.6 g/dL (146 g/L) for whites. In anemic KEEP participants, using the KDOQI definition, 52.5% were African American, 32.9% were white, and 8.1% were Hispanic (Table 3) . Conversely, in anemic NHANES participants, 50.1% were white, 31.5% were African American, and 13.2% were Hispanic. This reflects the overrepresentation of African Americans in KEEP compared with NHANES. Results were similar using the WHO anemia guidelines.
Compared with whites, African Americans in KEEP had greater odds of anemia (OR, 2.98; 95% CI, 2.80 to 3.16; P Ͻ 0.001 for KDOQI criteria; OR, 3.00; 95% CI, 2.81 to 3.20; P Ͻ 0.001 for WHO criteria; Table 5 ). Compared with non-Hispanics, Hispanic participants had lower odds of anemia (OR, 0.79; 95% CI, 0.70 to 0.88; P Ͻ 0.01 for KDOQI criteria; OR, 0.80; 95% CI, 0.71 to 0.90; P Ͻ 0.001 for WHO criteria).
Other Factors Associated With Anemia in the KEEP Population
A greater proportion of advanced CKD (stages 3 to 5) was observed in anemic patients of all racial groups and various risk factors. However, it was not observed in the youngest KEEP age group (18 to 30 years), in which the prevalence of stage 1 CKD was greater (stage 1, 9.3%; stage 2, 2.4%; and stages 3 to 5, 3.0%; Table 4 ). Corresponding data were not available for the NHANES population because of unreliable estimates. Compared with the age group with the highest number of participants (ages 46 to 60 years), both younger and older age categories had greater odds of anemia by using the KDOQI definition, with the greatest odds observed in the Disease Outcomes Quality Initiative; NR, estimates not reliable. *KDOQI: hemoglobin level less than 13.5 g/dL (Ͻ135 g/L) for men and less than 12 g/dL (Ͻ120 g/L) for women. †WHO: hemoglobin level less than 13.0 g/dL (Ͻ130 g/L) for men and less than 12 g/dL (Ͻ120 g/L) for women.
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oldest age group (age Ͼ 75 years; OR, 2.20; 95% CI, 2.00 to 2.42; P Ͻ 0.01; Table 5 ). Results were similar using WHO criteria.
Other risk factors that significantly increased the odds of anemia included lower educational level, diabetes mellitus, hypertension, CVD, and CKD, with risk greatest for patients with diabetes and CKD (OR, 1.73; 95% CI, 1.63 to 1.83; P Ͻ 0.001 for patients with diabetes; OR, 1.73; 95% CI, 1.63 to 1.84; P Ͻ 0.001 for patients with CKD) using KDOQI guidelines. Results were similar using the WHO anemia definition (Table 5 ).
DISCUSSION
Our study highlights several major differences between a targeted community-based screening program (KEEP) and a generalizable population health survey (NHANES 1999 (NHANES -2004 . Greater percentages of KEEP participants were at risk of CKD and anemia, including African Americans, who were 3 times more prevalent in KEEP than NHANES. Risk factors for CKD and CVD 5, 9, 14 also were better represented in KEEP populations than in NHANES. For example, obesity was 1.4 times; hypertension was 2 times; and *KDOQI: hemoglobin level less than 13.5 g/dL (Ͻ135 g/L) for men and less than 12 g/dL (Ͻ120 g/L) for women. †WHO: hemoglobin level less than 13.0 g/dL (Ͻ130 g/L) for men and less than 12 g/dL (Ͻ120 g/L) for women.
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diabetes was 4 times more prevalent in KEEP than NHANES. Not surprisingly, the KEEP population had a greater rate of CKD, with an associated much greater prevalence of anemia; this value was 2.2 times greater than in the NHANES sample population. The greater prevalence of anemia observed in the KEEP cohort was consistent across sex, racial and ethnic groups, and CVD risk categories, except for smoking. The high prevalence of diabetes observed in the KEEP cohort, 26.8% compared with 6.7% in the NHANES sample population, likely is a major contributor to the greater prevalence of anemia in KEEP participants through its effect on risk of CKD and other mechanisms. 4 Anemia is common in patients with diabetes and often goes unrecognized and untreated. [17] [18] [19] Although eGFR and iron stores are the strongest predictors of hemoglobin levels in patients with diabetes, these factors do not fully account for the increased prevalence of anemia in the diabetic population. 4, 19 Other factors, such as absolute and/or relative erythropoietin deficiency, inflammation, and oxidative stress, may explain the development of anemia in patients with diabetes and CKD. Furthermore, accumulating evidence indicates that in patients with early diabetic nephropathy, anemia is a common finding and associated with erythropoietin deficiency. 4, 17 Although men had greater hemoglobin values than women, they also had greater rates of more advanced CKD. The KDOQI definition with a lower threshold for anemia detection in men (13.5 g/dL [135 g/L]) thus was more reflective of the severity of CKD observed in men, resulting in a 30% greater risk of anemia in men than women. This is in contrast to the WHO anemia definition, with a lower hemoglobin cutoff value for men (13.0 g/dL [130 g/L]) or a greater threshold for diagnosing anemia in men, which reversed the odds of anemia between sexes; women had a 32% greater risk of anemia than men using WHO criteria.
The greater prevalence of anemia in participants older than 60 years compared with those aged 46 to 60 years likely is a reflection of a greater rate of CKD in older participants and lower eGFRs with aging. 20 Conversely, the greater risk of anemia in younger KEEP participants may represent mechanisms of anemia other than CKD, given the lower prevalence and less severe CKD in younger participants. It also could reflect higher representation of women and African Americans, groups with a greater risk of anemia independent of CKD.
12,13
The lower prevalence of anemia in current smokers in both the KEEP and NHANES populations is consistent with previous data indicating greater hemoglobin levels in smokers caused by secondary erythrocytosis.
21 Cigarette smoking appears to cause a generalized upward shift of the hemoglobin distribution curve, thus decreasing the utility of hemoglobin levels to detect anemia in smokers.
22
Treatment of anemia is by identification of underlying cause, which, in patients with CKD, may be either functional or actual iron deficiency with or without erythropoietic hormone resistance or deficiency.
23 KEEP data include insufficient specific medication data to address anemia treatment in this study.
Findings from our study have potentially significant public health implications. Early recognition of anemia through a targeted screening program for populations at high risk of CKD may become important for the development of preventive and therapeutic strategies. Decreased working capacity, cognitive impairment, angina, and cardiorenal anemia syndrome, a triad of worsening anemia, worsening CKD, and worsening congestive heart failure, are potential consequences of anemia of CKD. 
